Tcrcure Biopharma Ltd.
Clinical trials sponsored by Tcrcure Biopharma Ltd., explained in plain language.
-
New CAR-T therapy takes on hard-to-treat lung cancer
Disease control Recruiting nowThis early study tests a new treatment called TC-D101 for people with a specific type of advanced small cell lung cancer that has come back or not responded to standard treatments. The therapy uses specially engineered immune cells (CAR-T cells) to target a protein called DLL3 on…
Phase: EARLY_PHASE1 • Sponsor: TCRCure Biopharma Ltd. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Engineered t cells take on Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new type of immune cell therapy (CAR-T) designed to target a protein called ALPP found on some advanced solid tumors. About 24 adults whose cancers have not responded to standard treatments will receive the therapy to see if it is safe and tolerable…
Phase: EARLY_PHASE1 • Sponsor: TCRCure Biopharma Ltd. • Aim: Disease control
Last updated May 04, 2026 16:24 UTC